Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.

GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.

Tencent-backed Douyu has successfully listed on Nasdaq after completing a $775m initial public offering that came after economic tensions forced a delay earlier this year.

IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.

Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.

PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.

Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.

The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.

PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.

AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.